Under the agreement, Nuclidium will provide PharmaLogic with the technology and raw material to enable it to produce Cu-61 radionuclides and radiopharmaceuticals, with the first product batch planned for 2023 at the company's facility in Los Angeles.

Nuclidium will retain all rights to its proprietary platforms and technologies, the company added.